Autologous Cytokine-Induced Killer Cell Immunotherapy Enhances Chemotherapy Efficacy against Multidrug-Resistant Tuberculosis
Objective. Multidrug-resistant tuberculosis (MDR-TB) causes persistent infection and challenges tuberculosis control worldwide. T cell-mediated immunity plays a critical role in controlling Mycobacterium tuberculosis (Mtb) infection, and therefore, enhancing Mtb-specific T cell immune responses repr...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2022/2943113 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550776047665152 |
|---|---|
| author | Peijun Tang Xingnian Chen Junchi Xu Yunlong Hu Zhijian Ye Xiafang Wang Yumei Xiao Xinghua Shen Jianping Zhang Yanjun Feng Cuilin Shi Xin Yu Lixian Yi Xinchun Chen Binfeng Lu Ping Xu Zhongwen Sun Meiying Wu |
| author_facet | Peijun Tang Xingnian Chen Junchi Xu Yunlong Hu Zhijian Ye Xiafang Wang Yumei Xiao Xinghua Shen Jianping Zhang Yanjun Feng Cuilin Shi Xin Yu Lixian Yi Xinchun Chen Binfeng Lu Ping Xu Zhongwen Sun Meiying Wu |
| author_sort | Peijun Tang |
| collection | DOAJ |
| description | Objective. Multidrug-resistant tuberculosis (MDR-TB) causes persistent infection and challenges tuberculosis control worldwide. T cell-mediated immunity plays a critical role in controlling Mycobacterium tuberculosis (Mtb) infection, and therefore, enhancing Mtb-specific T cell immune responses represents a promising therapeutic strategy against TB. Cytokine-induced killer (CIK) immunotherapy is based on autologous infusion of in vitro expanded bulk T cells, which include both pathogen-specific and nonspecific T cells from patient peripheral blood mononuclear cells (PBMC) into TB patients. Preclinical mouse studies have shown that the adoptive T cell therapy inhibited Mtb infection. However, the efficacy of CIK immunotherapy in the treatment of MDR-TB infection has not been evaluated in clinical trials. Methods. We performed a retrospective study of MDR-TB patients who received CIK immunotherapy in combination with anti-TB chemotherapy and those who had standard chemotherapy. Results. Our results showed that CIK immunotherapy in combination with anti-TB chemotherapy treatment increased the conversion rate of sputum smear and Mtb culture, alleviated symptoms, improved lesion absorption, and increased recovery. The kinetics of serology and immunology index monitoring data showed good safety profiles for the CIK treatment. Conclusion. Our study has provided strong evidence that CIK immunotherapy in combination with anti-TB chemotherapy is beneficial for MDR-TB patients. A multicenter clinical trial is warranted to evaluate CIK as a new immune therapy for MDR-TB. |
| format | Article |
| id | doaj-art-e7edf10e63a6427ab59c88d017f0f34c |
| institution | Kabale University |
| issn | 2314-7156 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-e7edf10e63a6427ab59c88d017f0f34c2025-02-03T06:05:54ZengWileyJournal of Immunology Research2314-71562022-01-01202210.1155/2022/2943113Autologous Cytokine-Induced Killer Cell Immunotherapy Enhances Chemotherapy Efficacy against Multidrug-Resistant TuberculosisPeijun Tang0Xingnian Chen1Junchi Xu2Yunlong Hu3Zhijian Ye4Xiafang Wang5Yumei Xiao6Xinghua Shen7Jianping Zhang8Yanjun Feng9Cuilin Shi10Xin Yu11Lixian Yi12Xinchun Chen13Binfeng Lu14Ping Xu15Zhongwen Sun16Meiying Wu17Department of TuberculosisDepartment of TuberculosisDepartment of TuberculosisDepartment of Clinical Medical LaboratoryDepartment of TuberculosisDepartment of TuberculosisDepartment of TuberculosisDepartment of TuberculosisDepartment of TuberculosisDepartment of TuberculosisDepartment of TuberculosisDepartment of TuberculosisDepartment of Medical TechnologyDepartment of Pathogen BiologyDepartment of ImmunologyDepartment of TuberculosisDepartment of Medical TechnologyDepartment of TuberculosisObjective. Multidrug-resistant tuberculosis (MDR-TB) causes persistent infection and challenges tuberculosis control worldwide. T cell-mediated immunity plays a critical role in controlling Mycobacterium tuberculosis (Mtb) infection, and therefore, enhancing Mtb-specific T cell immune responses represents a promising therapeutic strategy against TB. Cytokine-induced killer (CIK) immunotherapy is based on autologous infusion of in vitro expanded bulk T cells, which include both pathogen-specific and nonspecific T cells from patient peripheral blood mononuclear cells (PBMC) into TB patients. Preclinical mouse studies have shown that the adoptive T cell therapy inhibited Mtb infection. However, the efficacy of CIK immunotherapy in the treatment of MDR-TB infection has not been evaluated in clinical trials. Methods. We performed a retrospective study of MDR-TB patients who received CIK immunotherapy in combination with anti-TB chemotherapy and those who had standard chemotherapy. Results. Our results showed that CIK immunotherapy in combination with anti-TB chemotherapy treatment increased the conversion rate of sputum smear and Mtb culture, alleviated symptoms, improved lesion absorption, and increased recovery. The kinetics of serology and immunology index monitoring data showed good safety profiles for the CIK treatment. Conclusion. Our study has provided strong evidence that CIK immunotherapy in combination with anti-TB chemotherapy is beneficial for MDR-TB patients. A multicenter clinical trial is warranted to evaluate CIK as a new immune therapy for MDR-TB.http://dx.doi.org/10.1155/2022/2943113 |
| spellingShingle | Peijun Tang Xingnian Chen Junchi Xu Yunlong Hu Zhijian Ye Xiafang Wang Yumei Xiao Xinghua Shen Jianping Zhang Yanjun Feng Cuilin Shi Xin Yu Lixian Yi Xinchun Chen Binfeng Lu Ping Xu Zhongwen Sun Meiying Wu Autologous Cytokine-Induced Killer Cell Immunotherapy Enhances Chemotherapy Efficacy against Multidrug-Resistant Tuberculosis Journal of Immunology Research |
| title | Autologous Cytokine-Induced Killer Cell Immunotherapy Enhances Chemotherapy Efficacy against Multidrug-Resistant Tuberculosis |
| title_full | Autologous Cytokine-Induced Killer Cell Immunotherapy Enhances Chemotherapy Efficacy against Multidrug-Resistant Tuberculosis |
| title_fullStr | Autologous Cytokine-Induced Killer Cell Immunotherapy Enhances Chemotherapy Efficacy against Multidrug-Resistant Tuberculosis |
| title_full_unstemmed | Autologous Cytokine-Induced Killer Cell Immunotherapy Enhances Chemotherapy Efficacy against Multidrug-Resistant Tuberculosis |
| title_short | Autologous Cytokine-Induced Killer Cell Immunotherapy Enhances Chemotherapy Efficacy against Multidrug-Resistant Tuberculosis |
| title_sort | autologous cytokine induced killer cell immunotherapy enhances chemotherapy efficacy against multidrug resistant tuberculosis |
| url | http://dx.doi.org/10.1155/2022/2943113 |
| work_keys_str_mv | AT peijuntang autologouscytokineinducedkillercellimmunotherapyenhanceschemotherapyefficacyagainstmultidrugresistanttuberculosis AT xingnianchen autologouscytokineinducedkillercellimmunotherapyenhanceschemotherapyefficacyagainstmultidrugresistanttuberculosis AT junchixu autologouscytokineinducedkillercellimmunotherapyenhanceschemotherapyefficacyagainstmultidrugresistanttuberculosis AT yunlonghu autologouscytokineinducedkillercellimmunotherapyenhanceschemotherapyefficacyagainstmultidrugresistanttuberculosis AT zhijianye autologouscytokineinducedkillercellimmunotherapyenhanceschemotherapyefficacyagainstmultidrugresistanttuberculosis AT xiafangwang autologouscytokineinducedkillercellimmunotherapyenhanceschemotherapyefficacyagainstmultidrugresistanttuberculosis AT yumeixiao autologouscytokineinducedkillercellimmunotherapyenhanceschemotherapyefficacyagainstmultidrugresistanttuberculosis AT xinghuashen autologouscytokineinducedkillercellimmunotherapyenhanceschemotherapyefficacyagainstmultidrugresistanttuberculosis AT jianpingzhang autologouscytokineinducedkillercellimmunotherapyenhanceschemotherapyefficacyagainstmultidrugresistanttuberculosis AT yanjunfeng autologouscytokineinducedkillercellimmunotherapyenhanceschemotherapyefficacyagainstmultidrugresistanttuberculosis AT cuilinshi autologouscytokineinducedkillercellimmunotherapyenhanceschemotherapyefficacyagainstmultidrugresistanttuberculosis AT xinyu autologouscytokineinducedkillercellimmunotherapyenhanceschemotherapyefficacyagainstmultidrugresistanttuberculosis AT lixianyi autologouscytokineinducedkillercellimmunotherapyenhanceschemotherapyefficacyagainstmultidrugresistanttuberculosis AT xinchunchen autologouscytokineinducedkillercellimmunotherapyenhanceschemotherapyefficacyagainstmultidrugresistanttuberculosis AT binfenglu autologouscytokineinducedkillercellimmunotherapyenhanceschemotherapyefficacyagainstmultidrugresistanttuberculosis AT pingxu autologouscytokineinducedkillercellimmunotherapyenhanceschemotherapyefficacyagainstmultidrugresistanttuberculosis AT zhongwensun autologouscytokineinducedkillercellimmunotherapyenhanceschemotherapyefficacyagainstmultidrugresistanttuberculosis AT meiyingwu autologouscytokineinducedkillercellimmunotherapyenhanceschemotherapyefficacyagainstmultidrugresistanttuberculosis |